You are here

Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cIAI

Last updated on December 15, 2017

FOR MORE INFORMATION
Study Location
Multiple Cities, , Taiwan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Abdominal Abscess
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Hospitalized male or female patients greater than or equal to 18 years of age.

- Patients must be a candidate for or have had a laparotomy, or laparoscopy of an
intra-abdominal abscess.

- Patients with a complicated intra-abdominal infection such as:

- an intra-abdominal abscess;

- an intra-abdominal abscess (including liver and spleen) that develops in a
post-operative patient after receiving > 48 hours and less than or equal to 5
days of a non-study antibiotic. An intra-abdominal culture must be obtained from
the infected site.

- appendicitis complicated by perforation (grossly visible) and abscess and/or
periappendiceal abscess;

- perforated diverticulitis complicated by abscess formation or fecal
contamination;

- complicated cholecystitis with evidence of perforation or empyema;

- perforation of the large or small intestine with abscess, or fecal contamination;

- purulent peritonitis or peritonitis associated with fecal contamination;

- gastric or duodenal ulcer perforation with symptoms lasting at least 24 hours
prior to operation;

- traumatic bowel perforation with symptoms lasting at least 12 hours prior to
operation.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with any concomitant condition that, in the opinion of the investigator,
would preclude an evaluation of a response or make it unlikely that the contemplated
course of therapy or follow-up visits could be completed.

- Active or treated leukemia or systemic malignancy that required treatment with
chemotherapy, immunotherapy, radiation therapy or antineoplastic therapy within the
past 3 months, or any metastatic malignancy to the abdomen with life expectancy less
than 6 months.

- Anticipated length of antibiotic therapy less than 5 days.

NCT00488306
Pfizer
Completed
Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cIAI

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia
NCT03329092
All Genders
18+
Years
Multiple Sites
Intra-abdominal Infection
NCT00244088
All Genders
Candidemia, Peritonitis) Other Forms of Candida Infections(Intra-abdominal Abscess
NCT00802854
All Genders
0+
Years
Multiple Sites
Complicated Skin and Skin Structure Infections, Complicated Intra-abdominal Infections
NCT00683332
All Genders
0+
Years
Manila,
Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cIAI
A Multicenter, Open Label Study to Evaluate the Efficacy and Safety of Tigecycline to Treat Complicated Intra-Abdominal Infections (cIAI) in Hospitalized Patients
In light of tigecycline's activity against these resistant bacteria, tigecycline may represent a viable new therapy for complicated intra-abdominal infections.
To evaluate the efficacy and safety of tigecycline to treat complicated intra-abdominal infections in hospitalized patients. Both the clinical response profile and the microbiological response profile will be assessed. The primary endpoint will be clinical response within the microbiological evaluable population at the test-of-cure assessment.
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Abdominal Abscess
Drug: tigecycline
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
August 2007
Not Provided

Inclusion Criteria:

  • Hospitalized male or female patients greater than or equal to 18 years of age.
  • Patients must be a candidate for or have had a laparotomy, or laparoscopy of an intra-abdominal abscess.
  • Patients with a complicated intra-abdominal infection such as:

    • an intra-abdominal abscess;
    • an intra-abdominal abscess (including liver and spleen) that develops in a post-operative patient after receiving > 48 hours and less than or equal to 5 days of a non-study antibiotic. An intra-abdominal culture must be obtained from the infected site.
    • appendicitis complicated by perforation (grossly visible) and abscess and/or periappendiceal abscess;
    • perforated diverticulitis complicated by abscess formation or fecal contamination;
    • complicated cholecystitis with evidence of perforation or empyema;
    • perforation of the large or small intestine with abscess, or fecal contamination;
    • purulent peritonitis or peritonitis associated with fecal contamination;
    • gastric or duodenal ulcer perforation with symptoms lasting at least 24 hours prior to operation;
    • traumatic bowel perforation with symptoms lasting at least 12 hours prior to operation.

Exclusion Criteria:

  • Patients with any concomitant condition that, in the opinion of the investigator, would preclude an evaluation of a response or make it unlikely that the contemplated course of therapy or follow-up visits could be completed.
  • Active or treated leukemia or systemic malignancy that required treatment with chemotherapy, immunotherapy, radiation therapy or antineoplastic therapy within the past 3 months, or any metastatic malignancy to the abdomen with life expectancy less than 6 months.
  • Anticipated length of antibiotic therapy less than 5 days.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Taiwan
 
 
NCT00488306
3074A1-101994
Not Provided
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator: Trial Manager For Taiwan, [email protected]
Wyeth is now a wholly owned subsidiary of Pfizer
July 2009

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now